TY  - JOUR
T1  - QUestionable efficacy for naltrexone in patients with asp40—reply
AU  - Anton RF, Oroszi G, O’Malley S, et al
Y1  - 2009/07/01
N1  - 10.1001/archgenpsychiatry.2009.69
JO  - Archives of General Psychiatry
SP  - 796
EP  - 797
VL  - 66
IS  - 7
N2  - 
Dr Mattes is primarily concerned about our explanation as to why the positive gene × naltrexone interaction was only observed in the group receiving MM alone and not in those who received a more intensive CBI in addition to MM. In essence, Dr Mattes suggests that since CBI in its own right was “not very effective,” the explanation that CBI could wash out or override any direct naltrexone effect or any observable gene × naltrexone interaction is not convincing. In our primary article on the COMBINE Study results,2 we had reported that individuals receiving placebo in the context of CBI (with MM) did significantly better than those who did not receive CBI (those who received placebo and MM alone). This was one of the main findings in that study. In fact, naltrexone when added to CBI (with MM) was no better than placebo with CBI (with MM). Therefore, CBI was efficacious in its own right and naltrexone effects could not be significantly observed in the context of this moderately intensive specialized alcohol counseling.

SN  - 0003-990X
M3  - doi: 10.1001/archgenpsychiatry.2009.69
UR  - http://dx.doi.org/10.1001/archgenpsychiatry.2009.69
ER  -